Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics for patients with kidney disease. Headquartered in Cambridge, Massachusetts, the company specializes in treatments based on hypoxia-inducible factor (HIF) biology and complement inhibition. Its commercial portfolio primarily targets complications of chronic kidney disease, such as anemia and hyperphosphatemia.
Financial Statements
In thousands, USD
FY 2025
FY 2024
FY 2023
FY 2022
Total Revenues
236,196
160,180
194,623
292,484
Cost of Sales
39,462
63,177
74,149
85,568
Gross Profit
196,734
97,003
120,474
206,916
Selling, General & Administrative Expenses
107,480
106,545
100,233
138,601
Research & Development Expenses
62,359
37,652
63,079
129,986
Other Operating Expenses
3,396
3,278
3,418
19,108
Operating Profit
23,499
(50,472)
(46,256)
(80,779)
Interest Expense
(24,179)
(18,185)
(6,032)
(15,687)
Non-Operating Income
(3,041)
(753)
363
2,240
Total Non-Operating Income
(27,220)
(18,938)
(5,669)
(13,447)
Income Before Provision for Income Taxes
(3,721)
(69,410)
(51,925)
(94,226)
Provision for Income Taxes
1,624
—
—
—
Consolidated Net Income
(5,345)
(69,410)
(51,925)
(94,226)
Net Income Attributable to Common Shareholders
(5,345)
(69,410)
(51,925)
(94,226)
Basic EPS
-0.02
-0.33
-0.28
-0.52
Diluted EPS
-0.02
-0.33
-0.28
-0.52
Basic Weighted Average Shares Outstanding
257,158
210,947
187,465
182,783
Diluted Weighted Average Shares Outstanding
257,158
210,947
187,465
182,783
Shares Outstanding
265,425
224,849
194,583
184,136
FY 2025
FY 2024
FY 2023
FY 2022
Cash and Cash Equivalents
184,844
51,870
42,925
90,466
Total Cash and Cash Equivalents
184,844
51,870
42,925
90,466
Accounts Receivable
47,031
34,368
39,290
40,284
Total Trade Receivables
47,031
34,368
39,290
40,284
Inventories
15,610
16,243
15,691
21,568
Other Current Assets
5,470
11,350
20,243
32,864
Total Current Assets
252,955
113,831
118,149
185,182
Net Property, Plant & Equipment
4,885
10,418
16,045
34,372
Net Intangible Assets
—
—
36,042
72,084
Goodwill
59,044
59,044
59,044
59,044
Other Long-Term Assets
59,681
37,377
12,423
5,372
Total Assets
376,565
220,670
241,703
356,054
Accounts Payable
21,185
15,180
14,635
18,021
Accrued Expenses
121,716
63,460
67,735
75,777
Current Portion of Long-Term Debt
—
—
17,500
32,000
Unearned Revenue
2,681
—
—
3,738
Other Current Liabilities
17,356
2,274
—
—
Total Current Liabilities
162,938
80,914
99,870
129,536
Long-Term Debt
48,250
38,693
17,183
34,078
Leases
—
3,547
8,947
28,961
Other Long-Term Liabilities
132,767
146,701
146,287
158,249
Total Long-Term Liabilities
181,017
188,941
172,417
221,288
Total Liabilities
343,955
269,855
272,287
350,824
Common Stock
2
2
2
2
Additional Paid-in Capital
1,716,307
1,629,167
1,578,358
1,562,247
Accumulated Other Comprehensive Income
6
6
6
6
Retained Earnings
(1,683,705)
(1,678,360)
(1,608,950)
(1,557,025)
Total Common Shareholders' Equity
32,610
(49,185)
(30,584)
5,230
Total Shareholders' Equity
32,610
(49,185)
(30,584)
5,230
Total Liabilities and Shareholders' Equity
376,565
220,670
241,703
356,054
FY 2025
FY 2024
FY 2023
FY 2022
Net Income
(5,345)
(69,410)
(51,925)
(94,226)
Depreciation & Amortization
1,269
37,504
37,627
37,697
Share-Based Compensation Expense
11,283
7,775
9,317
17,849
Other Adjustments
44,313
23,148
2,324
(33,031)
Changes in Trade Receivables
(14,142)
4,046
994
11,297
Changes in Inventories
(23,125)
(28,401)
(2,542)
19,087
Changes in Accounts Payable
3,082
(1,364)
(5,244)
1,501
Changes in Accrued Expenses
48,530
(12,777)
(10,021)
(38,005)
Changes in Unearned Revenue
2,681
—
(3,738)
4,654
Changes in Other Operating Activities
(554)
(1,180)
(176)
23
Cash from Operating Activities
67,992
(40,659)
(23,384)
(73,154)
Capital Expenditure
(291)
(33)
—
(114)
Proceeds from Sale of Property, Plant & Equipment
172
—
—
—
Purchases of Intangible Assets
(7,807)
—
—
—
Cash from Investing Activities
(7,926)
(33)
—
(114)
Issuance of Long-Term Debt
10,000
45,000
—
—
Repayments of Long-Term Debt
(1,608)
(37,099)
(32,000)
(33,000)
Net Issuance / (Repayments) of Long-Term Debt
8,392
7,901
(32,000)
(33,000)
Issuance of Common Shares
68,363
43,034
6,794
7,598
Net Issuance / (Repurchases) of Common Shares
68,363
43,034
6,794
7,598
Other Financing Activities
(3,828)
(1,272)
—
40,000
Cash from Financing Activities
72,927
49,663
(25,206)
14,598
Increase / (Decrease) in Cash, Cash Equivalents and Restricted Cash